FDA's SrLC Database: A Compliance Tool Too Few Teams Are Using

The FDA's Drug Safety-related Labeling Changes (SrLC) database has been publicly available since January 2016, yet regulatory affairs teams across the industry continue to treat it as a passive reference rather than an active surveillance instrument. For QA directors and regulatory leads managing NDA- and BLA-regulated products, the database represents a structured, searchable record of every safety labeling update the agency has either required or recommended -- including mandatory changes issued under Section 505(o)(4) of the FD&C Act. Teams that are not systematically monitoring it are operating with an incomplete picture of the agency's postmarket safety posture.

The SrLC database covers updates to safety information within the Prescribing Information for human prescription drugs regulated under NDAs and human prescription biological products regulated under BLAs. Specifically, it tracks changes to the BOXED WARNING, CONTRAINDICATIONS, WARNINGS AND PRECAUTIONS, ADVERSE REACTIONS, DRUG INTERACTIONS, USE IN SPECIFIC POPULATIONS, and patient-facing labeling sections including Patient Counseling Information, Patient Information, and Medication Guides. The database supports two search modes: by drug name or active ingredient, and by date range -- giving regulatory teams the flexibility to monitor a specific product or scan for class-wide labeling trends across a defined period.

Understanding what the database does not cover is equally important for compliance planning. The SrLC database excludes updates to other Prescribing Information sections such as INDICATIONS AND USAGE and DOSAGE AND ADMINISTRATION. It does not capture labeling for generic drugs regulated under ANDAs, nonprescription products, or products regulated by the Center for Biologics Evaluation and Research -- including vaccines, allergenic products, blood and blood products, plasma derivatives, and cellular and gene therapy products. For those product categories, Drugs@FDA remains the authoritative source. Safety data predating January 2016 is available through the MedWatch website. Plant heads and QA directors should ensure their document control and signal-detection workflows account for these boundaries explicitly, rather than assuming the SrLC database provides universal coverage.

The agency's stated intent behind the database is direct: prompt access to new safety data by healthcare practitioners and patients is expected to better promote patient health. The FDA also notes that health care vendors integrate these labeling updates into systems frequently accessed by practitioners and patients, which means that labeling changes captured in the SrLC database can propagate rapidly into clinical decision-support tools and pharmacy systems. For regulatory affairs leads, this reinforces the operational urgency of monitoring the database in near-real time -- a labeling change that appears in a competitor's product profile today may signal an agency expectation that will reach your own product tomorrow, particularly where pharmacological class effects are under review.

The SrLC database was recently renamed to clarify that its records include both FDA-required Safety Labeling Changes under Section 505(o)(4) and updates to safety information recommended by the FDA or initiated by companies. That distinction matters for internal compliance documentation: a Section 505(o)(4)-required change carries a different regulatory weight and timeline obligation than a company-initiated supplement approval. Regulatory affairs teams building SOP frameworks around postmarket labeling surveillance should map their monitoring workflows to both categories, and cross-reference findings against the FDA's guidance for industry on Safety Labeling Changes -- Implementation of Section 505(o)(4) of the FD&C Act, issued June 2013. The SrLC database can be searched at the FDA's Drug Safety and Availability page; contact information for the Division of Drug Information at CDER is available for teams requiring clarification on specific entries.